(Total Views: 663)
Posted On: 10/02/2020 4:41:09 PM
Post# of 153903
Re: hobartknoll #59267
Hobart,
The EINDs, while anecdotal were strongly positive. Dr. Patterson’s analysis, especially documenting differences in RNA transcriptions pre and post leronlimab, reduction of viremia, restoration of CD4/CD8, give those EINDs much more weight than they would otherwise merit.
CD10, while missing primary endpoint, hit the clinically important secondary endpoint of NEWS2, as well as demonstrated statistically significant reduction in SAEs.
CD12 is the put up or shut up trial. Cytodyn is chugging along in pursuit of covid. No approvals or EUAs, but from the science side, everything so far has been positive.
We can argue until 2030 about management, but leronlimab remains very much in play for Covid. IMO more than any other therapeutic, thus my time on this board and money in this stock.
The EINDs, while anecdotal were strongly positive. Dr. Patterson’s analysis, especially documenting differences in RNA transcriptions pre and post leronlimab, reduction of viremia, restoration of CD4/CD8, give those EINDs much more weight than they would otherwise merit.
CD10, while missing primary endpoint, hit the clinically important secondary endpoint of NEWS2, as well as demonstrated statistically significant reduction in SAEs.
CD12 is the put up or shut up trial. Cytodyn is chugging along in pursuit of covid. No approvals or EUAs, but from the science side, everything so far has been positive.
We can argue until 2030 about management, but leronlimab remains very much in play for Covid. IMO more than any other therapeutic, thus my time on this board and money in this stock.
(7)
(0)
